{"id":"continuous-apomorphine-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Dyskinesias"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hallucinations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apomorphine acts as a non-selective dopamine receptor agonist, primarily binding to D2 and D3 dopamine receptors. In Parkinson's disease, continuous subcutaneous or intravenous infusion maintains steady dopamine receptor stimulation, reducing motor fluctuations and improving motor control compared to intermittent dosing. This approach bypasses the need for intact dopaminergic neurons and provides more stable dopaminergic signaling.","oneSentence":"Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:32.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced Parkinson's disease with motor fluctuations"}]},"trialDetails":[{"nctId":"NCT07219927","phase":"","title":"Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2025-03-31","conditions":"Parkinson Disease","enrollment":120},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT04887467","phase":"PHASE4","title":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2021-09-16","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT05213169","phase":"PHASE2, PHASE3","title":"Apomorphine in Severe Brain-injured Patients","status":"RECRUITING","sponsor":"University of Liege","startDate":"2021-06-18","conditions":"Disorder of Consciousness","enrollment":48},{"nctId":"NCT06080399","phase":"","title":"Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-02-15","conditions":"Parkinson Disease","enrollment":70},{"nctId":"NCT05405998","phase":"NA","title":"Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy (AUTAP)","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2022-12-01","conditions":"Parkinson Disease","enrollment":90},{"nctId":"NCT01039090","phase":"PHASE3","title":"Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2009-02","conditions":"Parkinsons's Disease","enrollment":21},{"nctId":"NCT03623828","phase":"PHASE2","title":"Treating Severe Brain-injured Patients With Apomorphine","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2018-10-03","conditions":"Disorder of Consciousness","enrollment":8},{"nctId":"NCT03793491","phase":"","title":"Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-18","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT02702076","phase":"PHASE2","title":"Apomorphine in Parkinson's Disease Patients With Visual Hallucinations","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2017-05","conditions":"Parkinson's Disease, Hallucinations, Visual","enrollment":35},{"nctId":"NCT00761228","phase":"PHASE2","title":"Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury","status":"SUSPENDED","sponsor":"NeuroHealing Pharmaceuticals Inc.","startDate":"2010-07","conditions":"Brain Injury","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous Apomorphine infusion","genericName":"Continuous Apomorphine infusion","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}